Application of the metabotype concept, i.e., the grouping of metabolically homogenuous subjects, would enable a tailored and efficient use of preventive measures against the development and onset of metabolic diseases. The concept as developed in enable, phase 1, showed promising results and thus needs to be further developed.
In the context of this project, reproducibility of the clustering procedure will be explored in another independent observantional studies. Also, possible improvement of the clustering process by inclusion of additional metabolic data, i.e., gut microbiome composition and activity, will be tested. For the sake of a broad application in daily practice, a reduction of the set of variables to ‚routinely ’measured clinical parameters will be explored. Finally, the metabotyping concept will be applied in intervention studies in enable. Differential metabolic reactions by metabotype are expected; the results may help to foster the high-risk group approach in primary disease prevention, i.e. successful intervention in high-risk metabotypes.
Prof. Dr. Jakob Linseisen
Selbständige Forschungsgruppe Klinische Epidemiologie
Helmholtz Zentrum München
Tel: +49 (0)89 3187-3202